(Q34657935)

3 August 2017

1 reference

title

Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies (English)

1 reference

3 August 2017

1 reference

Michael J Morris

1

1 reference

PubMed ID

12031864

3 August 2017

Howard I Scher

series ordinal

2

1 reference

3 August 2017

1 June 2002

1 reference

3 August 2017

1 reference

3 August 2017

11

1 reference

3 August 2017

1-2

1 reference

3 August 2017

13-23

1 reference

Clinical states in prostate cancer: toward a dynamic model of disease progression

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

p53 protein accumulation and gene mutation in the progression of human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Structure and biology of a carcinoma-associated mucin, MUC1.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside‐KLH Conjugate Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Clinical trials in relapsed prostate cancer: defining the target

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Central role of VDR conformations for understanding selective actions of vitamin D(3) analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Regulation of prostatic growth and function by peptide growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

The ubiquitin system for protein degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

The ubiquitin-proteasome pathway: on protein death and cell life

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

How proteolysis drives the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

An essential role for NF-kappaB in preventing TNF-alpha-induced cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Effects of Ca++ mobilization on expression of androgen-regulated genes: interference with androgen receptor-mediated transactivation by AP-I proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

Serum metalloproteinases and their inhibitors: markers for malignant potential

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900006-3

7 January 2021

10.1016/S0960-7404(02)00006-3

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

12031864